MedTrace Logo

Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome

NCT05354583 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2023-10-10

No results posted yet for this study

Summary

The treatment outcome of Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome has not been well studied. Investigators will perform a retrospective and prospective cohort study to determine the treatment outcome of Mycobacterium abscessus infection in patients with acquired interferon-gamma autoantibody syndrome compared with the infection in patients with chronic lung disease which is known to be the most common group of infection and have high rates of treatment failure. Investigators hypothesized that Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome has better outcome than infection in chronic lung disease.

Conditions

  • Mycobacterium Abscessus Infection
  • Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies
  • Nontuberculous Mycobacterial Pulmonary Infection

Interventions

DRUG

Appropriate treatment

Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment

Sponsors & Collaborators

  • King Chulalongkorn Memorial Hospital

    lead OTHER

Principal Investigators

  • Warat Usawakidwiree, M.D. · Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  • Chusana Suankratay, M.D., Ph.D. · Division of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354583 on ClinicalTrials.gov